SciSparc Stock Soars 17.65% on $5M Private Placement

On May 5, 2025, SciSparc's stock surged by 17.65% in pre-market trading, marking a significant rise for the company.

Aegis Capital Corp. recently acted as the exclusive placement agent for a $5.0 million private placement for SciSparc Ltd. This financial move is expected to bolster the company's resources and potentially drive further growth in its clinical and research endeavors.

SciSparc's stock price has been influenced by its ongoing clinical trials and the potential for breakthroughs in its therapeutic areas. The company's focus on developing innovative treatments for various medical conditions has garnered attention from investors, contributing to the recent surge in its stock price.